Which of the following biomarkers useful for acute kidney injury? 1. KIM-1 2. NGAL 3. IL-18 4. FABP
## **Core Concept**
The question assesses knowledge of biomarkers used for diagnosing acute kidney injury (AKI). Acute kidney injury is a sudden episode of kidney damage or failure, and early detection is crucial for timely intervention. Various biomarkers have been studied for their utility in diagnosing AKI.
## **Why the Correct Answer is Right**
The correct answer involves understanding the role of specific biomarkers in AKI:
- **KIM-1 (Kidney Injury Molecule-1)**: Expressed in the proximal tubules after ischemic or nephrotoxic injury, making it a specific marker for AKI.
- **NGAL (Neutrophil Gelatinase-Associated Lipocalin)**: Rapidly increases in the urine and plasma after AKI, serving as an early biomarker.
- **IL-18 (Interleukin-18)**: A cytokine involved in inflammation, and its levels increase in the urine following AKI, particularly useful for distinguishing AKI from other causes of kidney dysfunction.
- **FABP (Fatty Acid-Binding Protein)**: Specifically, L-FABP (Liver-type FABP) has been studied as a marker for AKI, reflecting renal tubular damage.
All these biomarkers have been researched for their potential in early detection of AKI, making an option that includes all of them as correct potentially right.
## **Why Each Wrong Option is Incorrect**
- **Option A:** If this option excludes one of the well-recognized biomarkers like NGAL or KIM-1, it's incorrect because it misses established markers.
- **Option B:** Similarly, if this option misses a validated biomarker like IL-18 or FABP, it's incorrect for the same reason.
- **Option C:** This would be incorrect if it inaccurately includes or excludes a biomarker not validated for AKI diagnosis.
## **Clinical Pearl / High-Yield Fact**
A key point to remember is that while these biomarkers show promise, **NGAL and KIM-1** are among the most studied and have shown utility in clinical settings for early detection of AKI. Their elevation can precede the increase in serum creatinine, offering a potential window for early intervention.
## **Correct Answer: D.**